Advertisement
IDNA vs XLV
Which ETF would AI Choose? iShares Genomics Immunology and Healthcare ETF (IDNA) vs. Health Care Select Sector SPDR Fund (XLV)
Key Takeaways
- IDNA provides targeted exposure to global companies focused on genomics, immunology, and bioengineering, while XLV delivers broad exposure to the U.S. large-cap health care sector within the S&P 500.
- IDNA maintains a concentrated portfolio of approximately 50 holdings with higher expense ratio of 0.47%, compared to XLV's approximately 60 holdings and low expense ratio of 0.08%.
- IDNA emphasizes innovative, often smaller or mid-cap biotech firms with global reach, whereas XLV prioritizes established large-cap leaders across pharmaceuticals, providers, and equipment.
- Both ETFs allocate nearly all assets to the health care sector, but IDNA carries higher volatility due to its thematic focus, while XLV offers greater diversification and liquidity.
- Structural differences position IDNA for investors seeking growth in emerging life sciences innovation and XLV for stable, core health care sector allocation.
- Cost efficiency and index methodology favor XLV for broad market participation, while IDNA suits thematic strategies with tolerance for concentration risk.
Introduction
Investors evaluating health care exposure often compare specialized thematic funds with broad sector benchmarks. The iShares Genomics Immunology and Healthcare ETF (IDNA) and Health Care Select Sector SPDR Fund (XLV) both target health care but pursue distinct strategies. IDNA focuses on genomics and immunology innovation globally, while XLV tracks the diversified U.S. health care component of the S&P 500. These ETFs do not compete directly but offer complementary or alternative approaches for investors seeking sector participation with differing risk and thematic profiles.
iShares Genomics Immunology and Healthcare ETF (IDNA) Overview
The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the NYSE FactSet Global Genomics and Immuno Biopharma Index. This rules-based, market-cap-weighted index selects developed- and emerging-market companies positioned to benefit from long-term advancements in genomics, immunology, and bioengineering. The fund holds approximately 50 securities, with top positions concentrated in firms such as Moderna, Twist Bioscience, and Iovance Biotherapeutics. Holdings span biotechnology and life sciences, with geographic exposure primarily in the United States and select international markets. As a passive thematic ETF, IDNA employs periodic rebalancing aligned with the index methodology. The expense ratio stands at 0.47%. Its structure emphasizes innovation-driven companies, resulting in a more concentrated and growth-oriented profile within health care.
Health Care Select Sector SPDR Fund (XLV) Overview
The Health Care Select Sector SPDR Fund (XLV) tracks the Health Care Select Sector Index, representing the health care portion of the S&P 500. This passive, market-cap-weighted fund provides exposure to approximately 60 large-cap U.S. companies across pharmaceuticals, health care equipment and supplies, providers and services, biotechnology, and life sciences tools. Top holdings typically include Eli Lilly, Johnson & Johnson, and AbbVie. XLV employs full replication and quarterly rebalancing to match the index. The expense ratio is 0.08%. As a sector ETF, it offers broad diversification within U.S. health care, with nearly all assets allocated to the sector and minimal international exposure. Its structure supports liquidity and cost efficiency for core sector allocations.
Industry and Thematic Backdrop
The health care sector encompasses pharmaceuticals, biotechnology, medical devices, and services, influenced by demographic trends such as aging populations, advances in personalized medicine, and ongoing innovation in genomics and immunology. Regulatory developments around drug pricing and approvals, along with macroeconomic factors including interest rate expectations and capital allocation to life sciences, shape the environment. Thematic growth in bioengineering attracts specialized investment, while broader sector stability benefits from established revenue streams of large pharmaceutical and provider companies. Risks include regulatory scrutiny, patent expirations, and shifts in research and development spending. Both ETFs operate within this landscape, with IDNA more sensitive to innovation cycles and XLV reflecting overall sector performance.
Performance and Positioning Comparison
In recent market cycles, IDNA has exhibited greater sensitivity to biotech-specific developments and innovation milestones, leading to higher volatility compared with the more stable trajectory of XLV. XLV benefits from the defensive characteristics and dividend contributions of large-cap holdings, supporting relative resilience during sector rotations. IDNA's global thematic tilt positions it for potential outperformance during periods of strong genomics momentum, while XLV provides balanced exposure across the health care value chain. Differences in concentration and market-cap focus drive distinct risk-return profiles, with XLV generally offering lower costs and broader liquidity.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to discover additional opportunities aligned with your strategy.
Tickeron AI Verdict
Based on structural characteristics including lower expense ratio, broader diversification, higher liquidity, and established index methodology, Tickeron’s AI would currently assign higher probability of favor to the Health Care Select Sector SPDR Fund (XLV) for most investors seeking efficient health care exposure. The iShares Genomics Immunology and Healthcare ETF (IDNA) may appeal in scenarios prioritizing thematic innovation and global biotech growth, subject to higher costs and concentration.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDNA is a StrongBuy and XLV is a StrongBuy.
IDNA sees MACD Histogram crosses below signal line
IDNA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 51 instances where the indicator turned negative. In 46 of the 51 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for IDNA moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 18 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
IDNA broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 60 cases where IDNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on IDNA as a result. In 75 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
Following a +5.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDNA advanced for three days, in 238 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 167 of 197 cases where IDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
XLV in upward trend: 10-day moving average broke above 50-day moving average on October 15, 2026
The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on XLV as a result. In 77 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for XLV just turned positive on October 09, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in 39 of 49 cases over the following month. The odds of a continued upward trend are 80%.
XLV moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 265 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 228 of 271 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
XLV broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
| IDNA | XLV | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 84% |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 79% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 84% |
| Advances ODDS (%) | 1 day ago 85% | 6 days ago 81% |
| Declines ODDS (%) | 8 days ago 87% | 2 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 84% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PIZ | 50.11 | 0.26 | +0.52% |
| Invesco Dorsey Wright Developed Markets Momentum ETF (PIZ) | |||
| SDMF | 27.38 | 0.09 | +0.35% |
| Simplify Dbi Cta Managed Futures Index ETF | |||
| RMRC | 25.62 | N/A | N/A |
| ARMOR Core Risk-Managed ETF (RMRC) | |||
| QGRD | 29.16 | -0.06 | -0.19% |
| Horizon Nasdaq-100 Defined Risk ETF (QGRD) | |||
| MAGS | 72.20 | -0.27 | -0.37% |
| Roundhill Magnificent Seven ETF (MAGS) | |||
IDNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDNA has been loosely correlated with FATE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if IDNA jumps, then FATE could also see price increases.
| Ticker / NAME | Correlation To IDNA | 1D Price Change % | ||
|---|---|---|---|---|
| IDNA | 100% | +3.96% | ||
| FATE - IDNA | 57% Loosely correlated | +10.75% | ||
| DNA - IDNA | 51% Loosely correlated | -2.09% | ||
| RCUS - IDNA | 51% Loosely correlated | +7.27% | ||
| SANA - IDNA | 51% Loosely correlated | +2.61% | ||
| BNGO - IDNA | 51% Loosely correlated | +2.05% | ||
More | ||||
XLV and
Correlation & Price change
A.I.dvisor indicates that over the last year, XLV has been closely correlated with LLY. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if XLV jumps, then LLY could also see price increases.